PMID- 25287828
OWN - NLM
STAT- MEDLINE
DCOM- 20141229
LR  - 20220408
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 32
IP  - 31
DP  - 2014 Nov 1
TI  - Prospective, randomized, multicenter, phase III study of fluorouracil, 
      leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in 
      advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de 
      Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le 
      Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study.
PG  - 3520-6
LID - 10.1200/JCO.2013.54.1011 [doi]
AB  - PURPOSE: To compare epirubicin, cisplatin, and capecitabine (ECX) with 
      fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatments in 
      patients with advanced gastric or esophagogastric junction (EGJ) adenocarcinoma. 
      PATIENTS AND METHODS: This open, randomized, phase III study was carried out in 
      71 centers. Patients with locally advanced or metastatic gastric or EGJ cancer 
      were randomly assigned to receive either ECX as first-line treatment (ECX arm) or 
      FOLFIRI (FOLFIRI arm). Second-line treatment was predefined (FOLFIRI for the ECX 
      arm and ECX for the FOLFIRI arm). The primary criterion was time-to-treatment 
      failure (TTF) of the first-line therapy. Secondary criteria were progression-free 
      survival (PFS), overall survival (OS), toxicity, and quality of life. RESULTS: In 
      all, 416 patients were included (median age, 61.4 years; 74% male). After a 
      median follow-up of 31 months, median TTF was significantly longer with FOLFIRI 
      than with ECX (5.1 v 4.2 months; P = .008). There was no significant difference 
      between the two groups in median PFS (5.3 v 5.8 months; P = .96), median OS (9.5 
      v 9.7 months; P = .95), or response rate (39.2% v 37.8%). First-line FOLFIRI was 
      better tolerated (overall rate of grade 3 to 4 toxicity, 69% v 84%; P < .001; 
      hematologic adverse events [AEs], 38% v 64.5%; P < .001; nonhematologic AEs: 53% 
      v 53.5%; P = .81). CONCLUSION: FOLFIRI as first-line treatment for advanced 
      gastric and EGJ cancer demonstrated significantly better TTF than did ECX. Other 
      outcome results indicate that FOLFIRI is an acceptable first-line regimen in this 
      setting and should be explored as a backbone regimen for targeted agents.
CI  - (c) 2014 by American Society of Clinical Oncology.
FAU - Guimbaud, Rosine
AU  - Guimbaud R
AD  - Rosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe 
      Louvet, Institut Mutualiste Montsouris; Thierry Andre, Hopital Saint Antoine; 
      Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance 
      Publique-Hopitaux de Paris); Pascal Hammel, Hopital Beaujon; Philippe Rougier, 
      Hopital Europeen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, 
      Marseille; Marc Ychou, Institut Regional du Cancer Val d'Aurelle, Montpellier; 
      Emilie Maillard, Federation Francophone de Cancerologie Digestive; Laurent 
      Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hopital 
      Avicenne, Bobigny; Suzanne Nguyen, Hopital General, Beauvais; Ahmed Azzedine, 
      Hopital General, Montelimard; Pierre-Luc Etienne, Clinique Armoricaine, 
      Saint-Brieuc; Eveline Boucher, Centre Eugene Marquis, Rennes; Christine 
      Rebischung, Hopital A. Michallon, Grenoble; Olivier Bouche, Centre Hospitalier 
      Universitaire Robert Debre, Reims, France. guimbaud.r@chu-toulouse.fr.
FAU - Louvet, Christophe
AU  - Louvet C
AD  - Rosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe 
      Louvet, Institut Mutualiste Montsouris; Thierry Andre, Hopital Saint Antoine; 
      Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance 
      Publique-Hopitaux de Paris); Pascal Hammel, Hopital Beaujon; Philippe Rougier, 
      Hopital Europeen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, 
      Marseille; Marc Ychou, Institut Regional du Cancer Val d'Aurelle, Montpellier; 
      Emilie Maillard, Federation Francophone de Cancerologie Digestive; Laurent 
      Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hopital 
      Avicenne, Bobigny; Suzanne Nguyen, Hopital General, Beauvais; Ahmed Azzedine, 
      Hopital General, Montelimard; Pierre-Luc Etienne, Clinique Armoricaine, 
      Saint-Brieuc; Eveline Boucher, Centre Eugene Marquis, Rennes; Christine 
      Rebischung, Hopital A. Michallon, Grenoble; Olivier Bouche, Centre Hospitalier 
      Universitaire Robert Debre, Reims, France.
FAU - Ries, Pauline
AU  - Ries P
AD  - Rosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe 
      Louvet, Institut Mutualiste Montsouris; Thierry Andre, Hopital Saint Antoine; 
      Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance 
      Publique-Hopitaux de Paris); Pascal Hammel, Hopital Beaujon; Philippe Rougier, 
      Hopital Europeen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, 
      Marseille; Marc Ychou, Institut Regional du Cancer Val d'Aurelle, Montpellier; 
      Emilie Maillard, Federation Francophone de Cancerologie Digestive; Laurent 
      Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hopital 
      Avicenne, Bobigny; Suzanne Nguyen, Hopital General, Beauvais; Ahmed Azzedine, 
      Hopital General, Montelimard; Pierre-Luc Etienne, Clinique Armoricaine, 
      Saint-Brieuc; Eveline Boucher, Centre Eugene Marquis, Rennes; Christine 
      Rebischung, Hopital A. Michallon, Grenoble; Olivier Bouche, Centre Hospitalier 
      Universitaire Robert Debre, Reims, France.
FAU - Ychou, Marc
AU  - Ychou M
AD  - Rosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe 
      Louvet, Institut Mutualiste Montsouris; Thierry Andre, Hopital Saint Antoine; 
      Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance 
      Publique-Hopitaux de Paris); Pascal Hammel, Hopital Beaujon; Philippe Rougier, 
      Hopital Europeen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, 
      Marseille; Marc Ychou, Institut Regional du Cancer Val d'Aurelle, Montpellier; 
      Emilie Maillard, Federation Francophone de Cancerologie Digestive; Laurent 
      Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hopital 
      Avicenne, Bobigny; Suzanne Nguyen, Hopital General, Beauvais; Ahmed Azzedine, 
      Hopital General, Montelimard; Pierre-Luc Etienne, Clinique Armoricaine, 
      Saint-Brieuc; Eveline Boucher, Centre Eugene Marquis, Rennes; Christine 
      Rebischung, Hopital A. Michallon, Grenoble; Olivier Bouche, Centre Hospitalier 
      Universitaire Robert Debre, Reims, France.
FAU - Maillard, Emilie
AU  - Maillard E
AD  - Rosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe 
      Louvet, Institut Mutualiste Montsouris; Thierry Andre, Hopital Saint Antoine; 
      Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance 
      Publique-Hopitaux de Paris); Pascal Hammel, Hopital Beaujon; Philippe Rougier, 
      Hopital Europeen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, 
      Marseille; Marc Ychou, Institut Regional du Cancer Val d'Aurelle, Montpellier; 
      Emilie Maillard, Federation Francophone de Cancerologie Digestive; Laurent 
      Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hopital 
      Avicenne, Bobigny; Suzanne Nguyen, Hopital General, Beauvais; Ahmed Azzedine, 
      Hopital General, Montelimard; Pierre-Luc Etienne, Clinique Armoricaine, 
      Saint-Brieuc; Eveline Boucher, Centre Eugene Marquis, Rennes; Christine 
      Rebischung, Hopital A. Michallon, Grenoble; Olivier Bouche, Centre Hospitalier 
      Universitaire Robert Debre, Reims, France.
FAU - Andre, Thierry
AU  - Andre T
AD  - Rosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe 
      Louvet, Institut Mutualiste Montsouris; Thierry Andre, Hopital Saint Antoine; 
      Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance 
      Publique-Hopitaux de Paris); Pascal Hammel, Hopital Beaujon; Philippe Rougier, 
      Hopital Europeen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, 
      Marseille; Marc Ychou, Institut Regional du Cancer Val d'Aurelle, Montpellier; 
      Emilie Maillard, Federation Francophone de Cancerologie Digestive; Laurent 
      Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hopital 
      Avicenne, Bobigny; Suzanne Nguyen, Hopital General, Beauvais; Ahmed Azzedine, 
      Hopital General, Montelimard; Pierre-Luc Etienne, Clinique Armoricaine, 
      Saint-Brieuc; Eveline Boucher, Centre Eugene Marquis, Rennes; Christine 
      Rebischung, Hopital A. Michallon, Grenoble; Olivier Bouche, Centre Hospitalier 
      Universitaire Robert Debre, Reims, France.
FAU - Gornet, Jean-Marc
AU  - Gornet JM
AD  - Rosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe 
      Louvet, Institut Mutualiste Montsouris; Thierry Andre, Hopital Saint Antoine; 
      Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance 
      Publique-Hopitaux de Paris); Pascal Hammel, Hopital Beaujon; Philippe Rougier, 
      Hopital Europeen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, 
      Marseille; Marc Ychou, Institut Regional du Cancer Val d'Aurelle, Montpellier; 
      Emilie Maillard, Federation Francophone de Cancerologie Digestive; Laurent 
      Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hopital 
      Avicenne, Bobigny; Suzanne Nguyen, Hopital General, Beauvais; Ahmed Azzedine, 
      Hopital General, Montelimard; Pierre-Luc Etienne, Clinique Armoricaine, 
      Saint-Brieuc; Eveline Boucher, Centre Eugene Marquis, Rennes; Christine 
      Rebischung, Hopital A. Michallon, Grenoble; Olivier Bouche, Centre Hospitalier 
      Universitaire Robert Debre, Reims, France.
FAU - Aparicio, Thomas
AU  - Aparicio T
AD  - Rosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe 
      Louvet, Institut Mutualiste Montsouris; Thierry Andre, Hopital Saint Antoine; 
      Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance 
      Publique-Hopitaux de Paris); Pascal Hammel, Hopital Beaujon; Philippe Rougier, 
      Hopital Europeen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, 
      Marseille; Marc Ychou, Institut Regional du Cancer Val d'Aurelle, Montpellier; 
      Emilie Maillard, Federation Francophone de Cancerologie Digestive; Laurent 
      Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hopital 
      Avicenne, Bobigny; Suzanne Nguyen, Hopital General, Beauvais; Ahmed Azzedine, 
      Hopital General, Montelimard; Pierre-Luc Etienne, Clinique Armoricaine, 
      Saint-Brieuc; Eveline Boucher, Centre Eugene Marquis, Rennes; Christine 
      Rebischung, Hopital A. Michallon, Grenoble; Olivier Bouche, Centre Hospitalier 
      Universitaire Robert Debre, Reims, France.
FAU - Nguyen, Suzanne
AU  - Nguyen S
AD  - Rosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe 
      Louvet, Institut Mutualiste Montsouris; Thierry Andre, Hopital Saint Antoine; 
      Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance 
      Publique-Hopitaux de Paris); Pascal Hammel, Hopital Beaujon; Philippe Rougier, 
      Hopital Europeen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, 
      Marseille; Marc Ychou, Institut Regional du Cancer Val d'Aurelle, Montpellier; 
      Emilie Maillard, Federation Francophone de Cancerologie Digestive; Laurent 
      Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hopital 
      Avicenne, Bobigny; Suzanne Nguyen, Hopital General, Beauvais; Ahmed Azzedine, 
      Hopital General, Montelimard; Pierre-Luc Etienne, Clinique Armoricaine, 
      Saint-Brieuc; Eveline Boucher, Centre Eugene Marquis, Rennes; Christine 
      Rebischung, Hopital A. Michallon, Grenoble; Olivier Bouche, Centre Hospitalier 
      Universitaire Robert Debre, Reims, France.
FAU - Azzedine, Ahmed
AU  - Azzedine A
AD  - Rosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe 
      Louvet, Institut Mutualiste Montsouris; Thierry Andre, Hopital Saint Antoine; 
      Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance 
      Publique-Hopitaux de Paris); Pascal Hammel, Hopital Beaujon; Philippe Rougier, 
      Hopital Europeen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, 
      Marseille; Marc Ychou, Institut Regional du Cancer Val d'Aurelle, Montpellier; 
      Emilie Maillard, Federation Francophone de Cancerologie Digestive; Laurent 
      Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hopital 
      Avicenne, Bobigny; Suzanne Nguyen, Hopital General, Beauvais; Ahmed Azzedine, 
      Hopital General, Montelimard; Pierre-Luc Etienne, Clinique Armoricaine, 
      Saint-Brieuc; Eveline Boucher, Centre Eugene Marquis, Rennes; Christine 
      Rebischung, Hopital A. Michallon, Grenoble; Olivier Bouche, Centre Hospitalier 
      Universitaire Robert Debre, Reims, France.
FAU - Etienne, Pierre-Luc
AU  - Etienne PL
AD  - Rosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe 
      Louvet, Institut Mutualiste Montsouris; Thierry Andre, Hopital Saint Antoine; 
      Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance 
      Publique-Hopitaux de Paris); Pascal Hammel, Hopital Beaujon; Philippe Rougier, 
      Hopital Europeen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, 
      Marseille; Marc Ychou, Institut Regional du Cancer Val d'Aurelle, Montpellier; 
      Emilie Maillard, Federation Francophone de Cancerologie Digestive; Laurent 
      Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hopital 
      Avicenne, Bobigny; Suzanne Nguyen, Hopital General, Beauvais; Ahmed Azzedine, 
      Hopital General, Montelimard; Pierre-Luc Etienne, Clinique Armoricaine, 
      Saint-Brieuc; Eveline Boucher, Centre Eugene Marquis, Rennes; Christine 
      Rebischung, Hopital A. Michallon, Grenoble; Olivier Bouche, Centre Hospitalier 
      Universitaire Robert Debre, Reims, France.
FAU - Boucher, Eveline
AU  - Boucher E
AD  - Rosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe 
      Louvet, Institut Mutualiste Montsouris; Thierry Andre, Hopital Saint Antoine; 
      Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance 
      Publique-Hopitaux de Paris); Pascal Hammel, Hopital Beaujon; Philippe Rougier, 
      Hopital Europeen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, 
      Marseille; Marc Ychou, Institut Regional du Cancer Val d'Aurelle, Montpellier; 
      Emilie Maillard, Federation Francophone de Cancerologie Digestive; Laurent 
      Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hopital 
      Avicenne, Bobigny; Suzanne Nguyen, Hopital General, Beauvais; Ahmed Azzedine, 
      Hopital General, Montelimard; Pierre-Luc Etienne, Clinique Armoricaine, 
      Saint-Brieuc; Eveline Boucher, Centre Eugene Marquis, Rennes; Christine 
      Rebischung, Hopital A. Michallon, Grenoble; Olivier Bouche, Centre Hospitalier 
      Universitaire Robert Debre, Reims, France.
FAU - Rebischung, Christine
AU  - Rebischung C
AD  - Rosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe 
      Louvet, Institut Mutualiste Montsouris; Thierry Andre, Hopital Saint Antoine; 
      Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance 
      Publique-Hopitaux de Paris); Pascal Hammel, Hopital Beaujon; Philippe Rougier, 
      Hopital Europeen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, 
      Marseille; Marc Ychou, Institut Regional du Cancer Val d'Aurelle, Montpellier; 
      Emilie Maillard, Federation Francophone de Cancerologie Digestive; Laurent 
      Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hopital 
      Avicenne, Bobigny; Suzanne Nguyen, Hopital General, Beauvais; Ahmed Azzedine, 
      Hopital General, Montelimard; Pierre-Luc Etienne, Clinique Armoricaine, 
      Saint-Brieuc; Eveline Boucher, Centre Eugene Marquis, Rennes; Christine 
      Rebischung, Hopital A. Michallon, Grenoble; Olivier Bouche, Centre Hospitalier 
      Universitaire Robert Debre, Reims, France.
FAU - Hammel, Pascal
AU  - Hammel P
AD  - Rosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe 
      Louvet, Institut Mutualiste Montsouris; Thierry Andre, Hopital Saint Antoine; 
      Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance 
      Publique-Hopitaux de Paris); Pascal Hammel, Hopital Beaujon; Philippe Rougier, 
      Hopital Europeen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, 
      Marseille; Marc Ychou, Institut Regional du Cancer Val d'Aurelle, Montpellier; 
      Emilie Maillard, Federation Francophone de Cancerologie Digestive; Laurent 
      Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hopital 
      Avicenne, Bobigny; Suzanne Nguyen, Hopital General, Beauvais; Ahmed Azzedine, 
      Hopital General, Montelimard; Pierre-Luc Etienne, Clinique Armoricaine, 
      Saint-Brieuc; Eveline Boucher, Centre Eugene Marquis, Rennes; Christine 
      Rebischung, Hopital A. Michallon, Grenoble; Olivier Bouche, Centre Hospitalier 
      Universitaire Robert Debre, Reims, France.
FAU - Rougier, Philippe
AU  - Rougier P
AD  - Rosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe 
      Louvet, Institut Mutualiste Montsouris; Thierry Andre, Hopital Saint Antoine; 
      Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance 
      Publique-Hopitaux de Paris); Pascal Hammel, Hopital Beaujon; Philippe Rougier, 
      Hopital Europeen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, 
      Marseille; Marc Ychou, Institut Regional du Cancer Val d'Aurelle, Montpellier; 
      Emilie Maillard, Federation Francophone de Cancerologie Digestive; Laurent 
      Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hopital 
      Avicenne, Bobigny; Suzanne Nguyen, Hopital General, Beauvais; Ahmed Azzedine, 
      Hopital General, Montelimard; Pierre-Luc Etienne, Clinique Armoricaine, 
      Saint-Brieuc; Eveline Boucher, Centre Eugene Marquis, Rennes; Christine 
      Rebischung, Hopital A. Michallon, Grenoble; Olivier Bouche, Centre Hospitalier 
      Universitaire Robert Debre, Reims, France.
FAU - Bedenne, Laurent
AU  - Bedenne L
AD  - Rosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe 
      Louvet, Institut Mutualiste Montsouris; Thierry Andre, Hopital Saint Antoine; 
      Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance 
      Publique-Hopitaux de Paris); Pascal Hammel, Hopital Beaujon; Philippe Rougier, 
      Hopital Europeen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, 
      Marseille; Marc Ychou, Institut Regional du Cancer Val d'Aurelle, Montpellier; 
      Emilie Maillard, Federation Francophone de Cancerologie Digestive; Laurent 
      Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hopital 
      Avicenne, Bobigny; Suzanne Nguyen, Hopital General, Beauvais; Ahmed Azzedine, 
      Hopital General, Montelimard; Pierre-Luc Etienne, Clinique Armoricaine, 
      Saint-Brieuc; Eveline Boucher, Centre Eugene Marquis, Rennes; Christine 
      Rebischung, Hopital A. Michallon, Grenoble; Olivier Bouche, Centre Hospitalier 
      Universitaire Robert Debre, Reims, France.
FAU - Bouche, Olivier
AU  - Bouche O
AD  - Rosine Guimbaud, Centre Hospitalier Universitaire Toulouse, Toulouse; Christophe 
      Louvet, Institut Mutualiste Montsouris; Thierry Andre, Hopital Saint Antoine; 
      Jean-Marc Gornet, Centre Hospitalier Universitaire Saint Louis (Assistance 
      Publique-Hopitaux de Paris); Pascal Hammel, Hopital Beaujon; Philippe Rougier, 
      Hopital Europeen Georges Pompidou, Paris; Pauline Ries, Institut Paoli Calmettes, 
      Marseille; Marc Ychou, Institut Regional du Cancer Val d'Aurelle, Montpellier; 
      Emilie Maillard, Federation Francophone de Cancerologie Digestive; Laurent 
      Bedenne, Centre Hospitalier Universitaire, Dijon; Thomas Aparicio, Hopital 
      Avicenne, Bobigny; Suzanne Nguyen, Hopital General, Beauvais; Ahmed Azzedine, 
      Hopital General, Montelimard; Pierre-Luc Etienne, Clinique Armoricaine, 
      Saint-Brieuc; Eveline Boucher, Centre Eugene Marquis, Rennes; Christine 
      Rebischung, Hopital A. Michallon, Grenoble; Olivier Bouche, Centre Hospitalier 
      Universitaire Robert Debre, Reims, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT00374036
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20141006
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0W860991D6 (Deoxycytidine)
RN  - 3Z8479ZZ5X (Epirubicin)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - 7673326042 (Irinotecan)
RN  - Q20Q21Q62J (Cisplatin)
RN  - Q573I9DVLP (Leucovorin)
RN  - U3P01618RT (Fluorouracil)
RN  - XT3Z54Z28A (Camptothecin)
RN  - IFL protocol
SB  - IM
CIN - Nat Rev Clin Oncol. 2014 Dec;11(12):684. PMID: 25331178
EIN - J Clin Oncol. 2015 Apr 20;33(12):1416. PMID: 25883365
CIN - J Clin Oncol. 2015 Jul 20;33(21):2410-1. PMID: 26077234
CIN - J Clin Oncol. 2015 Jul 20;33(21):2410. PMID: 26077236
CIN - J Clin Oncol. 2015 Jul 20;33(21):2409. PMID: 26077239
MH  - Adenocarcinoma/*drug therapy/*pathology
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & 
      dosage/*therapeutic use
MH  - Camptothecin/administration & dosage/analogs & derivatives
MH  - Capecitabine
MH  - Cisplatin/administration & dosage
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - Epirubicin/administration & dosage
MH  - Esophagogastric Junction/*pathology
MH  - Female
MH  - Fluorouracil/administration & dosage/analogs & derivatives
MH  - Follow-Up Studies
MH  - France
MH  - Humans
MH  - Irinotecan
MH  - Leucovorin/administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Quality of Life
MH  - Stomach Neoplasms/*drug therapy/*pathology
MH  - Survival Analysis
MH  - Treatment Outcome
EDAT- 2014/10/08 06:00
MHDA- 2014/12/30 06:00
CRDT- 2014/10/08 06:00
PHST- 2014/10/08 06:00 [entrez]
PHST- 2014/10/08 06:00 [pubmed]
PHST- 2014/12/30 06:00 [medline]
AID - JCO.2013.54.1011 [pii]
AID - 10.1200/JCO.2013.54.1011 [doi]
PST - ppublish
SO  - J Clin Oncol. 2014 Nov 1;32(31):3520-6. doi: 10.1200/JCO.2013.54.1011. Epub 2014 
      Oct 6.